AMCP Joins Pharmaceutical Supply Chain Stakeholders to Support Access to Medications; AMCP Comments on COVID-19 Changes to Medicare Program; FDA Issues RFI on Improving the Orange Book; CMS Issues Final Medicare Part C and Part D Policy, Technical Rule
May issue includes: AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; AMCP Submits Comments on Proposed Part D MTM Program CMR Changes; Two Proposed Biosimilars Bills Fail to Advance
April issue includes: CARES Act Includes Changes Relevant to Managed Care Pharmacy, Substance Abuse Record Rules; HHS Authorizes Pharmacists to Order and Administer COVID19 Tests; AMCP Launches COVID19 Resource Center; AMCP Submits Comments on Proposed Medicare Advantage and Part D Rule; AMCP Comments to FDA and FTC on a Competitive Biosimilar Marketplace
June 2020 News & Views includes: ACHP/AMCP Survey Finds COVID-19 Has Shifted Consumer Behavior; Confidence in Pharmacies Remains High; AMCP Joins Peers in Promoting Patient Access to Rx Drugs; Cantrell Participates in PQA Fireside Chat to Describe how Managed Care Pharmacy Is Addressing the Pandemic; Univ. of California, San Francisco School of Pharmacy Wins AMCP Foundation’s 20th Annual P&T Competition; AMCP Foundation Awards Best Posters for Research on Opioid Use, Migraine Therapy, and Preterm Births; New AMCP Resource Focuses on Atherosclerotic Cardiovascular Disease
On June 1, 2020, the FDA issued a RFI requesting stakeholder comments on updating and improving the Orange Book. Please send any feedback to advocacy@amcp.org by August 14, 2020.
On June 1, 2020, the FDA issued a RFI soliciting stakeholder input on the listing of patent information in the Orange Book, including on the types of patent currently listed and how changes to current patent listing practices may impact drug product development. Please send any feedback to advocacy@amcp.org by August 14, 2020.
